A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders

Eric Hollander, Latha Soorya, William Chaplin, Evdokia Anagnostou, Bonnie P. Taylor, Casara J. Ferretti, Stacey Wasserman, Erika Swanson, Cara Settipani

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Objective: The effects of fluoxetine and placebo on repetitive behaviors and global severity were compared in adults with autism spectrum disorders (ASDs). Method: Adults with ASDs were enrolled in a 12-week double-blind placebo-controlled fluoxetine trial. Thirty-seven were randomly assigned to fluoxetine (N=22) or placebo (N=15). Dosage followed a fixed schedule, starting at 10 mg/day and increasing as tolerated up to 80 mg/ day. Repetitive behaviors were measured with the compulsion subscale of the Yale- Brown Obsessive Compulsive Scale; the Clinical Global Impression (CGI) improvement scale was used to rate improvement in obsessive-compulsive symptoms and overall severity. Results: There was a significant treatment-by- time interaction indicating a significantly greater reduction in repetitive behaviors across time for fluoxetine than for placebo. With overall response defined as a CGI global improvement score of 2 or less, there were significantly more responders at week 12 in the fluoxetine group than in the placebo group. The risk ratio was 1.5 for CGI global improvement (responders: fluoxetine, 35%; placebo, 0%) and 1.8 for CGI-rated improvement in obsessive-compulsive symptoms (responders: fluoxetine, 50%; placebo, 8%). Only mild and moderate side effects were observed. Conclusions: Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and CGI rating of obsessive-compulsive symptoms, as well as on the CGI overall improvement rating. Fluoxetine appeared to be well tolerated. These findings stand in contrast to findings in a trial of citalopram for childhood autism.

Original languageEnglish (US)
Pages (from-to)292-299
Number of pages8
JournalAmerican Journal of Psychiatry
Volume169
Issue number3
DOIs
StatePublished - Mar 1 2012

Fingerprint

Fluoxetine
Placebos
Autism Spectrum Disorder
Placebo
Controlled
Autism Spectrum Disorders
Citalopram
Placebo Effect
Autistic Disorder
Appointments and Schedules
Odds Ratio
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Arts and Humanities (miscellaneous)

Cite this

A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. / Hollander, Eric; Soorya, Latha; Chaplin, William; Anagnostou, Evdokia; Taylor, Bonnie P.; Ferretti, Casara J.; Wasserman, Stacey; Swanson, Erika; Settipani, Cara.

In: American Journal of Psychiatry, Vol. 169, No. 3, 01.03.2012, p. 292-299.

Research output: Contribution to journalArticle

Hollander, E, Soorya, L, Chaplin, W, Anagnostou, E, Taylor, BP, Ferretti, CJ, Wasserman, S, Swanson, E & Settipani, C 2012, 'A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders', American Journal of Psychiatry, vol. 169, no. 3, pp. 292-299. https://doi.org/10.1176/appi.ajp.2011.10050764
Hollander, Eric ; Soorya, Latha ; Chaplin, William ; Anagnostou, Evdokia ; Taylor, Bonnie P. ; Ferretti, Casara J. ; Wasserman, Stacey ; Swanson, Erika ; Settipani, Cara. / A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. In: American Journal of Psychiatry. 2012 ; Vol. 169, No. 3. pp. 292-299.
@article{bf8ae71f884949c4b7ddf588f1d184e8,
title = "A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders",
abstract = "Objective: The effects of fluoxetine and placebo on repetitive behaviors and global severity were compared in adults with autism spectrum disorders (ASDs). Method: Adults with ASDs were enrolled in a 12-week double-blind placebo-controlled fluoxetine trial. Thirty-seven were randomly assigned to fluoxetine (N=22) or placebo (N=15). Dosage followed a fixed schedule, starting at 10 mg/day and increasing as tolerated up to 80 mg/ day. Repetitive behaviors were measured with the compulsion subscale of the Yale- Brown Obsessive Compulsive Scale; the Clinical Global Impression (CGI) improvement scale was used to rate improvement in obsessive-compulsive symptoms and overall severity. Results: There was a significant treatment-by- time interaction indicating a significantly greater reduction in repetitive behaviors across time for fluoxetine than for placebo. With overall response defined as a CGI global improvement score of 2 or less, there were significantly more responders at week 12 in the fluoxetine group than in the placebo group. The risk ratio was 1.5 for CGI global improvement (responders: fluoxetine, 35{\%}; placebo, 0{\%}) and 1.8 for CGI-rated improvement in obsessive-compulsive symptoms (responders: fluoxetine, 50{\%}; placebo, 8{\%}). Only mild and moderate side effects were observed. Conclusions: Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and CGI rating of obsessive-compulsive symptoms, as well as on the CGI overall improvement rating. Fluoxetine appeared to be well tolerated. These findings stand in contrast to findings in a trial of citalopram for childhood autism.",
author = "Eric Hollander and Latha Soorya and William Chaplin and Evdokia Anagnostou and Taylor, {Bonnie P.} and Ferretti, {Casara J.} and Stacey Wasserman and Erika Swanson and Cara Settipani",
year = "2012",
month = "3",
day = "1",
doi = "10.1176/appi.ajp.2011.10050764",
language = "English (US)",
volume = "169",
pages = "292--299",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "3",

}

TY - JOUR

T1 - A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders

AU - Hollander, Eric

AU - Soorya, Latha

AU - Chaplin, William

AU - Anagnostou, Evdokia

AU - Taylor, Bonnie P.

AU - Ferretti, Casara J.

AU - Wasserman, Stacey

AU - Swanson, Erika

AU - Settipani, Cara

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Objective: The effects of fluoxetine and placebo on repetitive behaviors and global severity were compared in adults with autism spectrum disorders (ASDs). Method: Adults with ASDs were enrolled in a 12-week double-blind placebo-controlled fluoxetine trial. Thirty-seven were randomly assigned to fluoxetine (N=22) or placebo (N=15). Dosage followed a fixed schedule, starting at 10 mg/day and increasing as tolerated up to 80 mg/ day. Repetitive behaviors were measured with the compulsion subscale of the Yale- Brown Obsessive Compulsive Scale; the Clinical Global Impression (CGI) improvement scale was used to rate improvement in obsessive-compulsive symptoms and overall severity. Results: There was a significant treatment-by- time interaction indicating a significantly greater reduction in repetitive behaviors across time for fluoxetine than for placebo. With overall response defined as a CGI global improvement score of 2 or less, there were significantly more responders at week 12 in the fluoxetine group than in the placebo group. The risk ratio was 1.5 for CGI global improvement (responders: fluoxetine, 35%; placebo, 0%) and 1.8 for CGI-rated improvement in obsessive-compulsive symptoms (responders: fluoxetine, 50%; placebo, 8%). Only mild and moderate side effects were observed. Conclusions: Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and CGI rating of obsessive-compulsive symptoms, as well as on the CGI overall improvement rating. Fluoxetine appeared to be well tolerated. These findings stand in contrast to findings in a trial of citalopram for childhood autism.

AB - Objective: The effects of fluoxetine and placebo on repetitive behaviors and global severity were compared in adults with autism spectrum disorders (ASDs). Method: Adults with ASDs were enrolled in a 12-week double-blind placebo-controlled fluoxetine trial. Thirty-seven were randomly assigned to fluoxetine (N=22) or placebo (N=15). Dosage followed a fixed schedule, starting at 10 mg/day and increasing as tolerated up to 80 mg/ day. Repetitive behaviors were measured with the compulsion subscale of the Yale- Brown Obsessive Compulsive Scale; the Clinical Global Impression (CGI) improvement scale was used to rate improvement in obsessive-compulsive symptoms and overall severity. Results: There was a significant treatment-by- time interaction indicating a significantly greater reduction in repetitive behaviors across time for fluoxetine than for placebo. With overall response defined as a CGI global improvement score of 2 or less, there were significantly more responders at week 12 in the fluoxetine group than in the placebo group. The risk ratio was 1.5 for CGI global improvement (responders: fluoxetine, 35%; placebo, 0%) and 1.8 for CGI-rated improvement in obsessive-compulsive symptoms (responders: fluoxetine, 50%; placebo, 8%). Only mild and moderate side effects were observed. Conclusions: Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and CGI rating of obsessive-compulsive symptoms, as well as on the CGI overall improvement rating. Fluoxetine appeared to be well tolerated. These findings stand in contrast to findings in a trial of citalopram for childhood autism.

UR - http://www.scopus.com/inward/record.url?scp=84858971972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858971972&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.2011.10050764

DO - 10.1176/appi.ajp.2011.10050764

M3 - Article

C2 - 22193531

AN - SCOPUS:84858971972

VL - 169

SP - 292

EP - 299

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 3

ER -